MedTrace Logo

Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke

NCT07241520 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1096

Last updated 2026-01-06

No results posted yet for this study

Summary

This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

SHPL-49 Injection

2 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7 days.

DRUG

Placebo Injection

2 ampoules of Placebo Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7days.

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Shanghai Hutchison Pharmaceuticals Limited

    lead INDUSTRY

Principal Investigators

  • Yongjun Wang, Master · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-08
Primary Completion
2027-06-30
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07241520 on ClinicalTrials.gov